RecruitingRecruiting
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701 · Eidos Therapeutics, a BridgeBio company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
About this study
Study AG10-404 is an open-label study to investigate the long-term effects of acoramidis on cardiac functional and structural improvement, and the effects on cardiac amyloid burden in participants with ATTR-CM using two types of imaging, cardiac MRI and echocardiograms to track changes in heart structure and amyloid buildup over time.
Up to approximately 150 participants (ages 18-80) will be enrolled. Participants will receive study drug (712 mg equivalent to 800 mg of acoramidis hydrochloride) orally twice daily from Day 1 through Month 36. The study duration for an individual participant is approximately 38 months, including up to 45 days for screening, 36 months for open-label treatment and 1 month follow-up after the last dose of study drug. In-clinic visits will occur at Day 1, Day 28, Month 6, and every 6 months up to Month 36. Phone visits will occur at Month 3 and every 6 months thereafter up to Month 33. Participants will be followed throughout their participation in this study and for 30 days (+7 days) after the last dose of study drug.
Eligibility criteria
Key Inclusion Criteria:
* Participants aged 18 to 80
* Confirmed diagnosis of ATTR-CM requiring targeted therapy
* At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) \>35%; left ventricular (LV) wall thickness ≥12 mm.
* Heart failure condition has been clinically stable for at least 6 weeks prior to screening.
Key Exclusion Criteria:
* Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator).
* Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.
* Hemodynamic instability.
* Likely to undergo heart transplantation within 12 months from screening.
* Confirmed diagnosis of AL amyloidosis at screening.
* At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.
* Prior or current treatment with acoramidis.
Study design
Enrollment target: 150 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-28
Estimated completion: 2030-11
Last updated: 2026-11-19
Interventions
Drug: Acoramidis (AG10) oral tablet
Primary outcomes
- • To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM. (Month 36)
Sponsor
Eidos Therapeutics, a BridgeBio company · industry
Contacts & investigators
ContactMedical Information · contact · medinfo@bridgebio.com · 1-844-550-2246
All locations (9)
Johns Hopkins University 056Recruiting
Baltimore, Maryland, United States
Washington University in St. Louis - 065Recruiting
St Louis, Missouri, United States
Philadelphia Heart Institute - 030Recruiting
Philadelphia, Pennsylvania, United States
National Heart Centre - Singapore - 418Recruiting
Singapore, Singapore
Hospital Universitario Puerta de Hierro - 203Recruiting
Majadahonda, Madrid, Spain
Hospital Universitari de Bellvitge 249Recruiting
Barcelona, Spain
Hospital Universitario Juan Ramon Jimenez - 237Recruiting
Huelva, Spain
Hospital Clinico Universitario de Salamanca - 236Recruiting
Salamanca, Spain
Hospital Universitario Son Llatzer - 224Recruiting
Son Ferriol, Spain